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Patients were categorized according to baseline disease severity using MMSE score: 
mild (21-26), moderate (15-20), moderately severe/severe (< 15). Costs associated with 
patient and caregiver health care, patient social care and informal care were evalu-
ated using information from the Resource Use in Dementia instrument (RUD) and 
the data collection form. The primary objective was the estimation of total cost over 
the 18 months period. Total cost was estimated by applying country-specific unit 
costs. Supervision time and caregiver medical costs were excluded from the base 
case analysis. Imputation methods were used for missing cost data. Results: 419 
patients were enrolled (2010-2011) in 33 centers in France, 289 (69%) remained in the 
study at 18 months. Reasons for discontinuation were subject institutionalization 
(n= 65), death (n= 21) or other reason (n= 44). Total mean cumulative costs over the 
18-month period were estimated to be respectively 24140€ (21561-26863), 34287€ 
(30357-38939) and 44171€ (40050-48755) for mild, moderate and moderately severe/
severe patients (p< 0.001) with caregiver informal care cost accounting for approxi-
mately half of the total costs (52%, 53%, 51% respectively) (excluding supervision 
time). Mean overall monthly caregiver time increased over the 18-month period in 
each severity group, mainly driven by supervision time without significant differ-
ence between severity groups in terms of change from baseline. ConClusions: 
This longitudinal study showed that costs increase with AD severity. Informal care 
cost represents the largest part of total societal cost at each intermediate time point.
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objeCtives: In recent years, mental health problems have increased and people with 
mental disorders become more prevalent. This study aims to estimate the economic 
burden of people with mental disorders in Korea. Methods: The study evaluated the 
economic burden for people with mental disorders between 2008 and 2011 by sex and 
age. Direct and indirect costs were estimated using a prevalence based approach and 
calculated based on the four nationwide databases for people with disabilities(Korea 
National Health Insurance Corporation, the National Disability Registry of Ministry of 
Health and Welfare, the Korea National Statistical Offices’ records of cause of death, 
and National Survey on Persons with disabilities). The direct costs stem from both 
primary medical and non medical expenditures directly associated with mental dis-
orders. The indirect costs are estimated based on costs of lost productivity due to 
morbidity and premature mortality by applying a 3% of discount rate. Results: The 
results showed increases in both the prevalence of mental disorders by 1.2 times(from 
67,126 to 83,035) and total economic burden by 1.6 times(from $349.2 million to $562.6 
million) during 2008-2011. The proportions of direct costs over total economic burden 
were 89%($310.9 million) in 2008 and 91%($512.0 million) in 2011 and the proportions 
of indirect costs were 11%($38.4 million) and 9%($50.6 million) respectively. In addi-
tion, direct costs for male were 1.4 times higher than direct costs for female. The 
highest total socioeconomic costs($134.8 million~$201.4 million) were incurred by 
people aged 40-49 years. ConClusions: The prevalence and economic burden of 
mental disorders associated with direct costs increased for the years 2008 and 2011 
in Korea. These findings provide underlying evidence for mental health care improve-
ments and future studies are needed to investigate pharmacological and other social 
costs for mental disorders.
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objeCtives: Mental disorders constitute a major health problem with severe com-
plications and a significant impact on quality of life.This study is the first compre-
hensive study on the direct and indirect costs of mental disorders (schizophrenia, 
bipolar affective disorder, depressive episode, recurrent depressive disorder and 
reaction to severe stress, and adjustment disorders) and associated complications in 
Poland. Methods: In order to estimate the direct medical costs of mental disorders 
and their complications, including the costs of outpatient consultation, hospitaliza-
tion, rehabilitation, and drugs, data from the National Health Fund were used with 
related etiological fraction calculus. Indirect costs embraced costs of lost productiv-
ity due to absenteeism and inability to work (handicap) caused by these diseaeses, 
and costs of lost productivity due to the premature mortality. They were calcu-
lated upon Social Insurance Institution and Central Statistic Office datasets using 
human capital method. Results: Mental disorders is a cause of significant sickness 
absence and incapacity for work and therefore is associated with a growing pro-
ductivity decline in Poland. The share of indirect costs consitute almost 70% of total 
costs and indirect costs amounted to 760 mln EUR. The highest direct costs are asso-
ciated with treatment of mental disorders-related complications. ConClusions: 
The results of this study show that indirect costs can be higher than direct costs, and 
therefore cannot be ignored in health care decision-making processes. A major part 
of the total cost of analyzed mental disordes is indirect costs caused by productivity 
losses due to absenteeism and inability to work (65%). Most of these disorders can 
be successfully treated. The use of health care resources should be planned not only 
to cut direct costs of treatment but also to consider the social impact of the disease, 
through effective treatment to minimize indirect costs.
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objeCtives: Mental and behavioural disorders contributed 12.9% of the total bur-
den of disease in Australia, and pharmaceuticals are recommended as treatment 
objeCtives: Atypical antipsychotic-induced weight gain and metabolic side effects 
are key contributors to discontinuations and relapses among patients with schizo-
phrenia. Current treatment guidelines in Scotland recommend aripiprazole for 
adults with schizophrenia who are at risk of weight gain. Lurasidone is an atypical 
antipsychotic associated with a favourable metabolic side effect profile. The objec-
tive of this study was to conduct a cost-utility analysis to compare lurasidone with 
aripiprazole, and a budget impact analysis of introducing lurasidone treatment to 
patients with schizophrenia in the Scottish setting. Methods: A 10-year Markov 
model, incorporating a 6-week acute phase and a maintenance phase across three 
health states (stable on treatment, stable not on treatment, and relapse), was con-
structed. Baseline risks of discontinuation and relapse were derived from lurasi-
done clinical studies. Relative efficacy was taken from indirect comparisons. Costs 
included: drug therapy; relapse; outpatient; primary and residential care. Utility 
estimates were taken from literature. The budget impact analysis considered the 
difference between the acquisition cost of lurasidone per patient per year (PPPY) 
and the acquisition costs PPPY of medicines estimated to be displaced by lurasidone, 
and assumed that the uptake rate of lurasidone would be approximately 66% of that 
seen for aripiprazole in its first five years in the UK. Results: Lurasidone yielded 
a cost saving of £3,554 and a small quality-adjusted life-year (QALY) improve-
ment compared with aripiprazole. Deterministic sensitivity analysis indicated 
that results were sensitive to relapse rates. Probabilistic sensitivity analysis sug-
gested that lurasidone had the highest expected net benefit at all willingness-to-
pay thresholds. Lurasidone acquisition cost was £1,183 PPPY; the cost of displaced 
medicines was £1,182 PPPY. Lurasidone was therefore a budget neutral treatment 
option. ConClusions: Our analyses indicate that lurasidone is a clinically and 
cost-effective treatment option, which should have limited impact on prescribing 
budgets, when compared with aripiprazole.
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objeCtives: To calculate the variation in the drug cost involved in the treatment of 
depression during 2013-2015. Methods: Standard Treatment Guidelines (STG), 4th 
edition were perused to understand the management of depression. Current Index 
of Medical Specialities (CIMS) Oct. – Jan. 2015 issue were used to capture the price 
of drugs. Annual cost of drug treatment and its variation was studied. Results: 
According to STG, drugs needed for the treatment of depression includes Fluoxetine 
or Sertraline or Escitalopram or Venlafaxine or Mirtazapine or Imipramine or 
Amitryptylline. If we initiate the treatment with Fluoxetine 20mg OD, then the mini-
mum and maximum cost of treatment was found to be Rs.986-1789 annually. A total 
of 81% variation was observed in its minimum and maximum cost. Likewise, if the 
treatment is initiated with Amitryptylline 75mg OD, then we observed a variation of 
190% in its minimum and maximum cost of treatment. Similarly, 127% variation was 
noted for Escitalopram 10mg OD. ConClusions: A maximum of 3 fold variation was 
noted in the minimum and maximum cost of Amitryptylline. In Indian market a huge 
price variation exist, which is needed to regulate in order to maintain uniformity.
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objeCtives: The low reimbursed price of some “typical” antipsychotics could lead 
pharmaceutical companies to withdraw them from a given market, as a consequence 
of an unfavorable cost/revenue ratio. Aim of this work was to evaluate the clinical 
and economic implications of such an occurrence, i.e. of the “forced switch” of sta-
ble psychiatric patients. Methods: A Markov model was developed to identify all 
the possible scenarios related to the transition process from chlorpromazine and 
haloperidol to quetiapine (as possible examples). To replicate the “history” of a large 
number of hypothetical individual patients, a Monte Carlo simulation was performed. 
The outcomes of the switching and their impact were assessed using the estimated 
mean frequencies of the “lost to follow-up”, “died” and “stable condition” states, plus 
the estimated overall number of visits and ADRs. Transition probabilities and costs, 
from the perspective of NHS, were taken from published literature. A sensitivity 
analysis was also performed. Results: The “work” runs were performed with 500 
cohorts of 2000 subjects each, the simulations reached convergence after 26 cycles 
(corresponding to one year). Data analysis allowed to infer that 91% of the patients 
in treatment with chlorpromazine and haloperidol would be in stable conditions 
after one year from switching to quetiapine and that the incidence of ADRs would 
be 24 for 100 patients. During the first year of treatment each patient would return 
to the prescribing physician between 2-3 times. The “once-only” direct cost of the 
transition would be 1.5 - 2.5 million euros in Italy, followed by 5-7 million per year 
for new drug costs. ConClusions: This simulation confirms that, for both patients 
and NHS, “staying” with the present therapy would represent a better and more cost 
effective solution than switching, even if a higher reimbursed price were to be granted.
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objeCtives: To describe 18-month health care resource use and costs associated 
with Alzheimer’s disease (AD) for patients and caregivers in France, stratified by AD 
severity at baseline. Methods: 18-month, prospective, multi-center, cohort study 
conducted in France, Germany and UK. Enrolled outpatients were > 55 years, diag-
nosed with probable AD (NINCDS-ADRDA) and had an informal caregiver available. 
